What alternative medication can be used to manage fibromyalgia and generalized anxiety disorder in a patient with morbid obesity discontinuing duloxetine due to side effects?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Alternative Medication for Fibromyalgia and Generalized Anxiety Disorder After Duloxetine Discontinuation

Pregabalin 150 mg twice daily (300 mg/day total) is the optimal alternative medication for this patient, as it effectively treats both fibromyalgia pain and generalized anxiety disorder while having a weight-neutral or modest weight gain profile that is less problematic than alternatives in a patient with morbid obesity. 1

Rationale for Pregabalin as First Choice

  • Pregabalin has Level Ia, Grade A evidence for reducing pain in fibromyalgia, with patients more likely to achieve 30% pain reduction (RR 1.38,95% CI 1.25 to 1.51) compared to placebo 1

  • Pregabalin demonstrates anxiolytic effects that address the patient's generalized anxiety disorder, making it a dual-purpose medication 2

  • The recommended dosing starts at 75 mg twice daily, increasing to 150 mg twice daily within 1 week based on tolerance, with no additional benefit at 600 mg/day but increased dose-dependent adverse reactions 1

  • Pregabalin improves sleep quality, which is particularly relevant given the patient is already taking cyclobenzaprine (Flexeril) for sleep 1

Why Not Other First-Line Options

  • Amitriptyline should be avoided in this patient despite its Level Ia, Grade A evidence for fibromyalgia, because tricyclic antidepressants cause significant weight gain, which is contraindicated in a patient with morbid obesity 1

  • Milnacipran (Savella) is another SNRI like duloxetine and may cause similar side effects including hot flashes, making it a poor choice after duloxetine failure due to tolerability issues 3, 1

  • The patient is already taking cyclobenzaprine (Flexeril), so adding another sedating medication like amitriptyline would create excessive sedation and anticholinergic burden 1

Important Monitoring and Titration

  • Start pregabalin at 75 mg twice daily for the first week to assess tolerability, particularly monitoring for dizziness and somnolence 1

  • Increase to the target dose of 150 mg twice daily (300 mg/day total) after one week if tolerated 1

  • Do not escalate beyond 450 mg/day, as higher doses provide no additional benefit but significantly increase adverse events 1

  • Reassess pain levels, anxiety symptoms, and side effects every 4-8 weeks to evaluate treatment efficacy 1

Critical Pitfalls to Avoid

  • Do not add gabapentin if pregabalin is chosen, as they bind to identical targets with the same mechanism, making this combination pharmacologically redundant 1

  • Do not prescribe strong opioids or corticosteroids for fibromyalgia, as they lack efficacy and cause significant harm 3, 1

  • Avoid escalating pregabalin beyond 450 mg/day, as this provides no additional benefit but increases adverse events including weight gain, dizziness, and peripheral edema 1

If Pregabalin Fails or Is Not Tolerated

  • Second option: Tramadol is recommended for pain management with Level Ib, Grade A evidence when first-line medications are ineffective, though it should be used with caution given opioid-related risks 3, 1

  • Consider non-pharmacological interventions as essential adjuncts: heated pool therapy with or without exercise (Level IIa, Grade B evidence) and cognitive behavioral therapy for the anxiety component (Level Ia, Grade A evidence) 1, 4

  • If partial pain relief is achieved with pregabalin alone, consider adding tramadol rather than switching completely, as combination therapy may provide greater benefit 1

Addressing the Obesity Concern

  • Pregabalin can cause weight gain in some patients, but the effect is generally modest compared to tricyclic antidepressants like amitriptyline 1

  • The patient should be counseled about this potential side effect and encouraged to engage in the graduated exercise program recommended for fibromyalgia, which addresses both pain and weight management 1, 4

  • Monitor weight at each follow-up visit and consider dose reduction or medication switch if significant weight gain occurs (>5% body weight) 1

References

Guideline

Treatment for Fibromyalgia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Management of psychiatric comorbidity in fibromyalgia.

Current psychiatry reports, 2006

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Fibromyalgia Diagnosis and Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.